13F filerCIK 1061768 ↗

Baupost Group

You are looking at Q1 2017. See the latest, Q3 2026 →

Reported value

$8.49B

+11% on the quarter before

Positions

43

5 new, 6 sold out

Top 10

68.7%

of the value

Est. gain

+$414.1M

on stocks held all quarter

Est. return

+6.4%

on those stocks since Q4 2016

Filed

May 25, 2017 (amended)

On SEC EDGAR ↗

Positions as of Mar 31, 2017, from Baupost Group's 13F filing with the SEC. A 13F lists a manager's US-listed stocks and options at a quarter end and is filed up to 45 days later, so the fund may hold something else today. It leaves out short positions, cash and holdings outside the US.

Portfolio at a glance

  • New
  • Added
  • Cut
  • Same
  • Options

Each tile is a position, sized by its share, colored by what the fund did with it since Q4 2016. Striped tiles are options.

Cheniere Energy Inc12%
Viasat Inc9.9%
Twenty First Centy Fox Inc7.3%
Colony Northstar Inc7.3%
Synchrony Finl7.1%
Allergan Plc6.8%
19 others6.8%
Qorvo5.8%
Dell Technologies Inc4.3%
Pbf Energy Inc4.1%
Theravance Biopharma Inc4.0%
Antero Res Corp3.9%
Qualcomm3.5%
Twenty First Centy Fox Inc2.7%
Innoviva Inc1.9%
Keryx Biopharmaceuticals Inc1.9%
Veritiv Corp1.9%
Mckesson Corp1.7%
Forward Pharma A/S1.4%
Atara Biotherapeutics Inc1.3%
Cardinal Health Inc1.0%
Express Scripts Hldg Co1.0%
0.8%
0.8%
0.7%

Largest buys

Since Q4 2016, sized at quarter-end prices.

  1. Colony Northstar Inc~$618.5MNew, 0.0% → 7.3% of the portfolio+47,905,461 shares
  2. Qorvo~$492.6MNew, 0.0% → 5.8% of the portfolio+7,185,514 shares
  3. Qualcomm~$299.1MNew, 0.0% → 3.5% of the portfolio+5,216,000 shares
  4. Express Scripts Hldg Co~$81.0MNew, 0.0% → 1.0% of the portfolio+1,228,619 shares
  5. Silver Run Acquisition~$69.0MNew, 0.0% → 0.8% of the portfolio+6,615,554 shares
  6. Cascadian Therapeutics Inc~$18.9MAdded, 0.2% → 0.4% of the portfolio+4,554,413 shares
  7. Forward Pharma A/S~$4.5MAdded, 1.0% → 1.4% of the portfolio+208,107 shares

Largest sells

Since Q4 2016, sized at quarter-end prices.

  1. Northstar Asset Mgmt Group I~$279.1MSold out, 3.6% → 0.0% of the portfolio−18,705,000 shares
  2. Allergan Plc~$238.9MCut, 9.4% → 6.8% of the portfolio−1,000,000 shares
  3. Northstar Rlty Fin Corp~$220.8MSold out, 2.9% → 0.0% of the portfolio−14,577,134 shares
  4. Colony Cap Inc~$140.9MSold out, 1.8% → 0.0% of the portfolio−6,959,017 shares
  5. Synchrony Finl~$102.9MCut, 9.8% → 7.1% of the portfolio−3,000,000 shares
  6. Dell Technologies Inc~$64.1MCut, 4.8% → 4.3% of the portfolio−1,000,000 shares
  7. Innoviva Inc~$46.4MCut, 2.1% → 1.9% of the portfolio−3,357,820 shares
  8. American Intl Group Inc~$28.5MCut, 0.8% → 0.3% of the portfolio−1,335,305 shares
  9. Liberty Media Corp Delaware~$23.6MCut, 0.8% → 0.6% of the portfolio−1,000,000 shares
  10. Theravance Inc~$22.6MCut, 0.5% → 0.3% of the portfolio−23,750,000 shares

Holdings

As of Mar 31, 2017; changes in shares since Dec 31, 2016.

Positions, sorted by share of the portfolio
HoldingValue
Cheniere Energy IncCOM NEW · shares 0% · price +14.1%12.1%$1.03B+$126.9M
Viasat IncCOM · shares 0% · price −3.6%9.9%$839.8M−$31.6M
Twenty First Centy Fox IncCL A · shares 0% · price +15.5%7.3%$619.9M+$83.2M
Colony Northstar IncCL A COM · shares New7.3%$618.5M—
Synchrony FinlCOM · shares −15% · price −5.4%7.1%$605.9M−$34.8M
Allergan PlcSHS · shares −29% · price +13.8%6.8%$581.2M+$70.3M
QorvoCOM · shares New5.8%$492.6M—
Dell Technologies IncCOM CL V · shares −15% · price +16.6%4.3%$362.2M+$51.5M
Pbf Energy IncCL A · shares 0% · price −20.5%4.1%$348.6M−$89.8M
Theravance Biopharma IncCOM · shares 0% · price +15.5%4.0%$341.5M+$45.8M
Antero Res CorpCOM · shares 0% · price −3.6%3.9%$330.9M−$12.2M
QualcommCOM · shares New3.5%$299.1M—
Twenty First Centy Fox IncCL B · shares 0% · price +16.6%2.7%$231.3M+$33.0M
Innoviva IncCOM · shares −22% · price +29.3%1.9%$160.1M+$36.2M
Keryx Biopharmaceuticals IncCOM · shares 0% · price +5.1%1.9%$158.9M+$7.7M
Veritiv CorpCOM · shares 0% · price −3.6%1.9%$157.7M−$5.9M
Mckesson CorpCOM · shares 0% · price +5.6%1.7%$148.3M+$7.8M
Forward Pharma A/SSPONSORED ADR · shares +3.9% · price +43.4%1.4%$119.9M+$34.9M
Atara Biotherapeutics IncCOM · shares 0% · price +44.7%1.3%$110.1M+$34.0M
Cardinal Health IncCOM · shares 0% · price +13.3%0.99%$84.0M+$9.9M
Express Scripts Hldg CoCOM · shares New0.95%$81.0M—
Silver Run AcquisitionUNIT 99/99/9999 · shares New0.81%$69.0M—
Liberty Interactive CorpLBT VEN COM A NE · shares 0% · price +20.6%0.78%$65.9M+$11.3M
ChipMOS TechnologiesSPONSORED ADR · shares 0% · price +25.8%0.73%$62.3M+$12.8M
Credit Accep Corp MichCOM · shares 0% · price −8.3%0.57%$48.7M−$4.4M
Total 43 positions100%$8.49B+$414.1M

Price is a stock's reported value over its shares at the quarter end. The estimated gain is the shares held at both quarter ends times the change in that price: shares bought or sold during the quarter add nothing, options are left out, and a stock split is read into the earlier share count and price.

What made money

From Q4 2016 to Q1 2017: 36 stocks held throughout, up $414.1M (+6.4%).

  1. Cheniere Energy Inc+$126.9M+14%
  2. Twenty First Centy Fox Inc+$83.2M+16%
  3. Allergan Plc+$70.3M+14%
  4. Dell Technologies Inc+$51.5M+17%
  5. Theravance Biopharma Inc+$45.8M+15%
  6. Veritiv Corp−$5.9M−4%
  7. Antero Res Corp−$12.2M−4%
  8. Viasat Inc−$31.6M−4%
  9. Synchrony Finl−$34.8M−5%
  10. Pbf Energy Inc−$89.8M−20%

Estimated as in the holdings table: shares held at both quarter ends times the change in price; options left out.

Reported value by quarter

Pick a quarter to see what the fund held then.

$20.00B$10.00B$0
Q1 2016Q3 2026
Every quarter's filing
Each quarter's 13F filing, newest first
QuarterReported valueFiling
Q3 2026$5.05B−7%SEC ↗
Q2 2026$5.42B+6%SEC ↗
Q1 2026$5.12B−3%SEC ↗
Q4 2025$5.28B+10%SEC ↗
Q3 2025$4.79B+16%SEC ↗
Q2 2025$4.13B+18%SEC ↗
Q1 2025$3.50B+2%SEC ↗
Q4 2024$3.43B−2%SEC ↗
Q3 2024$3.52B−3%SEC ↗
Q2 2024$3.63B−0%SEC ↗
Q1 2024$3.65B−20%SEC ↗
Q4 2023$4.59B−12%SEC ↗
Q3 2023$5.21B−7%SEC ↗
Q2 2023$5.61B−4%SEC ↗
Q1 2023$5.85B−5%SEC ↗
Q4 2022$6.13B+6%SEC ↗
Q3 2022$5.79B−14%SEC ↗
Q2 2022$6.77B−27%SEC ↗
Q1 2022$9.30B−8%SEC ↗
Q4 2021$10.13B−7%SEC ↗
Q3 2021$10.88B−12%SEC ↗
Q2 2021$12.33B−2%SEC ↗
Q1 2021$12.56B+16%SEC ↗
Q4 2020$10.84B+17%SEC ↗
Q3 2020$9.25B+15%SEC ↗
Q2 2020$8.01B+18%SEC ↗
Q1 2020$6.77B−25%SEC ↗
Q4 2019$9.06B+3%SEC ↗
Q3 2019$8.83B−20%SEC ↗
Q2 2019$11.05B−7%SEC ↗
Q1 2019$11.90B+3%SEC ↗
Q4 2018$11.52B−12%SEC ↗
Q3 2018$13.06B+14%SEC ↗
Q2 2018$11.44B+10%SEC ↗
Q1 2018$10.37B+3%SEC ↗
Q4 2017$10.11B+26%SEC ↗
Q3 2017$8.02B−8%SEC ↗
Q2 2017$8.75B+3%SEC ↗
Q1 2017$8.49B+11%SEC ↗
Q4 2016$7.67B+9%SEC ↗
Q3 2016$7.04B−4%SEC ↗
Q2 2016$7.37B+6%SEC ↗
Q1 2016$6.92BSEC ↗

Subscribe to TheInference for free